Analysts are weighing in on recently public Bind Therapeutics (BIND -1%), whose most advanced drug candidate is BIND-014, a PSMA targeting Accurin containing docetaxel.
Credit Suisse starts the shares at Outperform. Price target is $21.
Cowen initiates at Outperform with a $30 price target.
Stifel starts BIND at Buy. Price target is $20.
JMP initiates at Market Outperform. Price target is $30.